Yuhong Du, PhD, MSc

Research Program

Discovery and Developmental Therapeutics
Phone Number

404-727-0354
Email Address

dyuhong@emory.edu

Biography

Yuhong Du, PhD, MSc, is an associate professor in the Department of Pharmacology and Chemical Biology at Emory University School of Medicine and the associate director of assay development and HTS at the Emory Chemical Biology Discovery Center. Dr. Du is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University in Atlanta, Georgia.

Education

Dr. Du received her PhD from the National University of Singapore in Life Sciences and Pharmacy and completed her postdoctoral fellowship in the Department of Pharmacology at Emory University. Prior to obtaining her PhD, she earned both her MSc and BSc from the School of Pharmacy at Shanghai Medical University.

Titles & Roles

Associate Professor, Department of Pharmacology and Chemical Biology

Emory University School of Medicine
Associate Director of Assay Development and HTS

Emory Chemical Biology Discovery Center

Research

Dr. Du uses high throughput screening technologies to discover small molecule leads for chemical biology and drug discovery against various diseases. Her expertise includes innovative high-throughput screening (HTS)/high-content screening (HCS) assay design and development, screening robotic operations, HTS/HCS data analysis and efficient project management as well as using label-free biosensors for oncogenic signaling studies.

Dr. Du is a founding member of the Emory Chemical Biology Discovery Center and has directed the design, acquisition, assembly and operation of the center's two advanced robotic screening systems to facilitate ultra-throughput screening (uHTS) and image-based phenotypic screens.

Title/Journal	Authors	Publication Date
A multiplexed time-resolved fluorescence resonance energy transfer ultrahigh-throughput screening assay for targeting the SMAD4-SMAD3-DNA complex. Journal of molecular cell biology	W Ouyang, Q Li, Q Niu, M Qui, H Fu, Y Du, X Mo	10/04/2024
Frequency-potency analysis of IgG+ memory B cells delineates neutralizing antibody responses at single-cell resolution. Cell reports	MK Tenggara, SH Oh, C Yang, HK Nariya, AM Metz, AA Upadhyay, DR Gudipati, L Guo, EG McGhee, K Gill, EG Viox, RD Mason, NA Doria-Rose, KE Foulds, JR Mascola, Y Du, H Fu, JD Altman, Q Yan, Z Sheng, SE Bosinger, R Kong	26/03/2024
Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM. PloS one	FM Bashore, VL Katis, Y Du, A Sikdar, D Wang, WJ Bradshaw, KA Rygiel, TM Leisner, R Chalk, S Mishra, CA Williams, O Gileadi, PE Brennan, JC Wiley, J Gockley, GA Cary, GW Carter, JE Young, KH Pearce, H Fu, AD Axtman	01/01/2024
Discovery of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimer's disease. The Journal of biological chemistry	Y Du, WJ Bradshaw, TM Leisner, JK Annor-Gyamfi, K Qian, FM Bashore, A Sikdar, FO Nwogbo, AA Ivanov, SV Frye, O Gileadi, PE Brennan, AI Levey, AD Axtman, KH Pearce, H Fu, VL Katis	01/12/2023
Fused Tetrahydroquinolines Are Interfering with Your Assay. Journal of medicinal chemistry	FM Bashore, J Annor-Gyamfi, Y Du, V Katis, F Nwogbo, RG Flax, SV Frye, KH Pearce, H Fu, TM Willson, DH Drewry, AD Axtman	09/11/2023
A Novel 7H-[1,2,4]Triazolo[3,4-b]thiadiazine-based Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Directed toward Treatment of Cystic Fibrosis. ACS medicinal chemistry letters	A Rab, X Yang, WF Tracy, JS Hong, D Joshi, C Manfredi, SS Ponnaluri, AA Kolykhalov, M Qui, H Fu, Y Du, HML Davies, EJ Sorscher	12/10/2023
Tumor microenvironment in a minipig model of spinal cord glioma. Journal of translational medicine	MS Tora, SG Neill, Y Lakhina, H Assed, M Zhang, PP Nagarajan, T Federici, J Gutierrez, KB Hoang, Y Du, K Lei, NM Boulis	27/09/2023
Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models. British journal of cancer	X Li, Y Chen, L Bai, R Zhao, Y Wu, ZR Xie, JM Wu, NJ Bowen, A Danaher, N Cook, D Li, M Qui, Y Du, H Fu, AO Osunkoya, O Kucuk, D Wu	01/09/2023
Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia. Journal of controlled release : official journal of the Controlled Release Society	JM Kelvin, ML Chimenti, DY Zhang, EK Williams, SG Moore, GM Humber, TA Baxter, LA Birnbaum, M Qui, H Zecca, A Thapa, J Jain, NT Jui, X Wang, H Fu, Y Du, ML Kemp, WA Lam, DK Graham, D DeRyckere, EC Dreaden	01/09/2023
Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML. Pharmaceutical research	JM Kelvin, J Jain, A Thapa, M Qui, LA Birnbaum, SG Moore, H Zecca, RJ Summers, JM Switchenko, E Costanza, B Uricoli, X Wang, NT Jui, H Fu, Y Du, D DeRyckere, DK Graham, EC Dreaden	01/09/2023
TMPRSS2 and SARS-CoV-2 SPIKE interaction assay for uHTS. Journal of molecular cell biology	D Cicka, Q Niu, M Qui, K Qian, E Miller, D Fan, X Mo, AA Ivanov, SG Sarafianos, Y Du, H Fu	03/08/2023
Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models. Translational oncology	L Bai, X Li, Y Yang, R Zhao, EZ White, A Danaher, NJ Bowen, CV Hinton, N Cook, D Li, AY Wu, M Qui, Y Du, H Fu, O Kucuk, D Wu	01/08/2023
Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM. bioRxiv : the preprint server for biology	FM Bashore, VL Katis, Y Du, A Sikdar, D Wang, WJ Bradshaw, KA Rygiel, TM Leisner, R Chalk, S Mishra, AC Williams, O Gileadi, PE Brennan, JC Wiley, J Gockley, GA Cary, GW Carter, JE Young, KH Pearce, H Fu, AD Axtman	29/07/2023
A multiplexed time-resolved fluorescence resonance energy transfer ultrahigh-throughput screening assay for targeting SMAD4-SMAD3-DNA complex. bioRxiv : the preprint server for biology	W Ouyang, Q Niu, M Qui, H Fu, Y Du, X Mo	15/07/2023
Cyclosporines Antagonize the Antiviral Activity of IFITMProteins by Redistributing Them toward the Golgi Apparatus. Biomolecules	D Prikryl, M Marin, TM Desai, Y Du, H Fu, GB Melikyan	03/06/2023
Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's disease. bioRxiv : the preprint server for biology	Y Du, WJ Bradshaw, TM Leisner, JK Annor-Gyamfi, K Qian, FM Bashore, A Sikdar, FO Nwogbo, AA Ivanov, SV Frye, O Gileadi, PE Brennan, AI Levey, AD Axtman, KH Pearce, H Fu, VL Katis	22/05/2023
Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML. bioRxiv : the preprint server for biology	JM Kelvin, J Jain, A Thapa, M Qui, LA Birnbaum, SG Moore, H Zecca, RJ Summers, E Costanza, B Uricoli, X Wang, NT Jui, H Fu, Y Du, D DeRyckere, DK Graham, EC Dreaden	15/03/2023
High-throughput screening strategies for space-based radiation countermeasure discovery. Life sciences in space research	KS Putt, Y Du, H Fu, ZY Zhang	01/11/2022
Correction for Puckett et al., "Integration of Apoptosis Signal-Regulating Kinase 1-Mediated Stress Signaling with the Akt/Protein Kinase B-IκB Kinase Cascade". Molecular and cellular biology	MC Puckett, EH Goldman, LM Cockrell, B Huang, AL Kasinski, Y Du, CY Wang, A Lin, H Ichijo, F Khuri, H Fu	20/10/2022
Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells. Acta pharmacologica Sinica	C Shu, X Zheng, A Wuhafu, D Cicka, S Doyle, Q Niu, D Fan, K Qian, AA Ivanov, Y Du, X Mo, H Fu	01/09/2022
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. Cell	X Mo, Q Niu, AA Ivanov, YH Tsang, C Tang, C Shu, Q Li, K Qian, A Wahafu, SP Doyle, D Cicka, X Yang, D Fan, MA Reyna, LAD Cooper, CS Moreno, W Zhou, TK Owonikoko, S Lonial, FR Khuri, Y Du, SS Ramalingam, GB Mills, H Fu	26/05/2022
A time-resolved fluorescence resonance energy transfer screening assay for discovery of protein-protein interaction modulators. STAR protocols	C Tang, Q Niu, D Cicka, Y Du, X Mo, H Fu	17/09/2021
Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer. Bioorganic & medicinal chemistry	X Yang, D Fan, AH Troha, HM Ahn, K Qian, B Liang, Y Du, H Fu, AA Ivanov	01/09/2021
A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation. Cancer discovery	YH Lo, KS Kolahi, Y Du, CY Chang, A Krokhotin, A Nair, WD Sobba, K Karlsson, SJ Jones, TA Longacre, AT Mah, B Tercan, A Sockell, H Xu, JA Seoane, J Chen, I Shmulevich, JS Weissman, C Curtis, A Califano, H Fu, GR Crabtree, CJ Kuo	01/06/2021
Hypomorph mutation-directed small-molecule protein-protein interaction inducers to restore mutant SMAD4-suppressed TGF-β signaling. Cell chemical biology	C Tang, X Mo, Q Niu, A Wahafu, X Yang, M Qui, AA Ivanov, Y Du, H Fu	20/05/2021
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Theranostics	X Li, L Gera, S Zhang, Y Chen, L Lou, LM Wilson, ZR Xie, G Sautto, D Liu, A Danaher, K Mamouni, Y Yang, Y Du, H Fu, O Kucuk, AO Osunkoya, J Zhou, D Wu	01/01/2021
Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells. Stem cell research & therapy	R Liu, D Li, F Sun, A Rampoldi, JT Maxwell, R Wu, P Fischbach, SM Castellino, Y Du, H Fu, A Mandawat, C Xu	05/11/2020
Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma. Journal of hematology & oncology	K Lei, X Gu, AG Alvarado, Y Du, S Luo, EH Ahn, SS Kang, B Ji, X Liu, H Mao, H Fu, HI Kornblum, L Jin, H Li, K Ye	21/10/2020
High expression of MKK3 is associated with worse clinical outcomes in African American breast cancer patients. Journal of translational medicine	X Yang, M Amgad, LAD Cooper, Y Du, H Fu, AA Ivanov	01/09/2020
Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screening. Journal of molecular cell biology	Y Du, X Li, Q Niu, X Mo, M Qui, T Ma, CJ Kuo, H Fu	01/08/2020
NSD3S stabilizes MYC through hindering its interaction with FBXW7. Journal of molecular cell biology	V Gonzalez-Pecchi, AK Kwan, S Doyle, AA Ivanov, Y Du, H Fu	03/07/2020
Human beige adipocytes for drug discovery and cell therapy in metabolic diseases. Nature communications	AM Singh, L Zhang, J Avery, A Yin, Y Du, H Wang, Z Li, H Fu, H Yin, S Dalton	02/06/2020
Subpopulation targeting of pyruvate dehydrogenase and GLUT1 decouples metabolic heterogeneity during collective cancer cell invasion. Nature communications	R Commander, C Wei, A Sharma, JK Mouw, LJ Burton, E Summerbell, D Mahboubi, RJ Peterson, J Konen, W Zhou, Y Du, H Fu, M Shanmugam, AI Marcus	24/03/2020
HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform to Reveal IAP Antagonists as Anti-cancer Immune Enhancers. Cell chemical biology	X Mo, C Tang, Q Niu, T Ma, Y Du, H Fu	21/03/2019
Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer. Molecular cancer therapeutics	Y Yang, K Mamouni, X Li, Y Chen, S Kavuri, Y Du, H Fu, O Kucuk, D Wu	01/09/2018
Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening. Scientific reports	ASA Mady, C Liao, N Bajwa, KJ Kump, FA Abulwerdi, KL Lev, L Miao, SM Grigsby, A Perdih, JA Stuckey, Y Du, H Fu, Z Nikolovska-Coleska	05/07/2018
Trifunctional High-Throughput Screen Identifies Promising Scaffold To Inhibit Grp94 and Treat Myocilin-Associated Glaucoma. ACS chemical biology	DJE Huard, VM Crowley, Y Du, RA Cordova, Z Sun, MO Tomlin, CA Dickey, J Koren, L Blair, H Fu, BSJ Blagg, RL Lieberman	20/04/2018
The OncoPPi Portal: an integrative resource to explore and prioritize protein-protein interactions for cancer target discovery. Bioinformatics (Oxford, England)	AA Ivanov, B Revennaugh, L Rusnak, V Gonzalez-Pecchi, X Mo, MA Johns, Y Du, LAD Cooper, CS Moreno, FR Khuri, H Fu	01/04/2018
Development of a Time-Resolved Fluorescence Resonance Energy Transfer Ultrahigh-Throughput Screening Assay for Targeting the NSD3 and MYC Interaction. Assay and drug development technologies	J Xiong, VG Pecchi, M Qui, AA Ivanov, X Mo, Q Niu, X Chen, H Fu, Y Du	01/01/2018
OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc. Oncogene	AA Ivanov, V Gonzalez-Pecchi, LF Khuri, Q Niu, Y Wang, Y Xu, Y Bai, X Mo, EV Prochownik, MA Johns, Y Du, FR Khuri, H Fu	19/10/2017
Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis. Journal of medicinal chemistry	Q Qi, O Obianyo, Y Du, H Fu, S Li, K Ye	14/09/2017
Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. Oncogene	X Guo, JL Koff, AB Moffitt, M Cinar, S Ramachandiran, Z Chen, JM Switchenko, M Mosunjac, SG Neill, KP Mann, M Bagirov, Y Du, Y Natkunam, HJ Khoury, MR Rossi, W Harris, CR Flowers, IS Lossos, LH Boise, SS Dave, J Kowalski, L Bernal-Mizrachi	20/07/2017
Aurora kinase A interacts with H-Ras and potentiates Ras-MAPK signaling. Oncotarget	M Umstead, J Xiong, Q Qi, Y Du, H Fu	25/04/2017
Corrigendum: The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies. Nature communications	Z Li, AA Ivanov, R Su, V Gonzalez-Pecchi, Q Qi, S Liu, P Webber, E McMillan, L Rusnak, C Pham, X Chen, X Mo, B Revennaugh, W Zhou, A Marcus, S Harati, X Chen, MA Johns, MA White, CS Moreno, LAD Cooper, Y Du, FR Khuri, H Fu	18/04/2017
AKT1, LKB1, and YAP1 Revealed as MYC Interactors with NanoLuc-Based Protein-Fragment Complementation Assay. Molecular pharmacology	X Mo, Q Qi, AA Ivanov, Q Niu, Y Luo, J Havel, R Goetze, S Bell, CS Moreno, LA Cooper, MA Johns, FR Khuri, Y Du, H Fu	01/04/2017
Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer's disease. Nature communications	Z Zhang, O Obianyo, E Dall, Y Du, H Fu, X Liu, SS Kang, M Song, SP Yu, C Cabrele, M Schubert, X Li, JZ Wang, H Brandstetter, K Ye	27/03/2017
The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies. Nature communications	Z Li, AA Ivanov, R Su, V Gonzalez-Pecchi, Q Qi, S Liu, P Webber, E McMillan, L Rusnak, C Pham, X Chen, X Mo, B Revennaugh, W Zhou, A Marcus, S Harati, X Chen, MA Johns, MA White, C Moreno, LA Cooper, Y Du, FR Khuri, H Fu	16/02/2017
Screening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors. Assay and drug development technologies	C Giroud, Y Du, M Marin, Q Min, NT Jui, H Fu, GB Melikyan	01/01/2017
MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development. PloS one	S Harati, LA Cooper, JD Moran, FO Giuste, Y Du, AA Ivanov, MA Johns, FR Khuri, H Fu, CS Moreno	01/01/2017
Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment. Cancer cell	L Gu, H Zhang, T Liu, S Zhou, Y Du, J Xiong, S Yi, CK Qu, H Fu, M Zhou	10/10/2016
Enabling systematic interrogation of protein-protein interactions in live cells with a versatile ultra-high-throughput biosensor platform. Journal of molecular cell biology	XL Mo, Y Luo, AA Ivanov, R Su, JJ Havel, Z Li, FR Khuri, Y Du, H Fu	01/06/2016
Downregulation of urea transporter UT-A1 activity by 14-3-3 protein. American journal of physiology. Renal physiology	X Feng, Z Li, Y Du, H Fu, JD Klein, H Cai, JM Sands, G Chen	01/07/2015
Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway. International journal of cancer	S Ramachandiran, A Adon, X Guo, Y Wang, H Wang, Z Chen, J Kowalski, UR Sunay, AN Young, T Brown, JC Mar, Y Du, H Fu, KP Mann, Y Natkunam, LH Boise, HI Saavedra, IS Lossos, L Bernal-Mizrachi	15/05/2015
Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3. Oncogene	Z Shi, Z Li, ZJ Li, K Cheng, Y Du, H Fu, FR Khuri	07/05/2015
High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors. Assay and drug development technologies	M Marin, Y Du, C Giroud, JH Kim, M Qui, H Fu, GB Melikyan	01/04/2015
Stress induces p38 MAPK-mediated phosphorylation and inhibition of Drosha-dependent cell survival. Molecular cell	Q Yang, W Li, H She, J Dou, DM Duong, Y Du, SH Yang, NT Seyfried, H Fu, G Gao, Z Mao	19/02/2015
Cables1 complex couples survival signaling to the cell death machinery. Cancer research	Z Shi, HR Park, Y Du, Z Li, K Cheng, SY Sun, Z Li, H Fu, FR Khuri	01/01/2015
Fluorescence polarization assay to quantify protein-protein interactions in an HTS format. Methods in molecular biology (Clifton, N.J.)	Y Du	01/01/2015
Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells. Oncoscience	PJ Webber, C Park, M Qui, SS Ramalingam, FR Khuri, H Fu, Y Du	01/01/2015
Synthesis and evaluation of bisbenzylidenedioxotetrahydrothiopranones as activators of endoplasmic reticulum (ER) stress signaling pathways and apoptotic cell death in acute promyelocytic leukemic cells. Journal of medicinal chemistry	KL Tan, A Ali, Y Du, H Fu, HX Jin, TM Chin, M Khan, ML Go	24/07/2014
Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensor motifs. Oncotarget	Z Li, HR Park, Z Shi, Z Li, CD Pham, Y Du, FR Khuri, Y Zhang, Q Han, H Fu	30/05/2014
The Emory Chemical Biology Discovery Center: leveraging academic innovation to advance novel targets through HTS and beyond. Combinatorial chemistry & high throughput screening	MA Johns, CL Meyerkord-Belton, Y Du, H Fu	01/03/2014
Ligands for glaucoma-associated myocilin discovered by a generic binding assay. ACS chemical biology	SD Orwig, PV Chi, Y Du, SE Hill, MA Cavitt, A Suntharalingam, KC Turnage, CA Dickey, S France, H Fu, RL Lieberman	21/02/2014
Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma. Organic & biomolecular chemistry	K Liu, D Zhang, J Chojnacki, Y Du, H Fu, S Grant, S Zhang	07/08/2013
Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models. Biochemical pharmacology	Q Zhang, S Zhai, L Li, X Li, H Zhou, A Liu, G Su, Q Mu, Y Du, B Yan	01/08/2013
A time-resolved fluorescence resonance energy transfer assay for high-throughput screening of 14-3-3 protein-protein interaction inhibitors. Assay and drug development technologies	Y Du, RW Fu, B Lou, J Zhao, M Qui, FR Khuri, H Fu	01/07/2013
Integration of apoptosis signal-regulating kinase 1-mediated stress signaling with the Akt/protein kinase B-IκB kinase cascade. Molecular and cellular biology	MC Puckett, EH Goldman, LM Cockrell, B Huang, AL Kasinski, Y Du, CY Wang, A Lin, H Ichijo, F Khuri, H Fu	01/06/2013
Ophiopogonin B-induced autophagy in non-small cell lung cancer cells via inhibition of the PI3K/Akt signaling pathway. Oncology reports	M Chen, Y Du, M Qui, M Wang, K Chen, Z Huang, M Jiang, F Xiong, J Chen, J Zhou, F Jiang, L Yin, Y Tang, L Ye, Z Zhan, JΑ Duan, HΑ Fu, X Zhang	01/02/2013
Ebselen and congeners inhibit NADPH oxidase 2-dependent superoxide generation by interrupting the binding of regulatory subunits. Chemistry & biology	SM Smith, J Min, T Ganesh, B Diebold, T Kawahara, Y Zhu, J McCoy, A Sun, JP Snyder, H Fu, Y Du, I Lewis, JD Lambeth	22/06/2012
Identification of blapsins A and B as potent small-molecule 14-3-3 inhibitors from the insect Blaps japanensis. Bioorganic & medicinal chemistry letters	YM Yan, HQ Dai, Y Du, B Schneider, H Guo, DP Li, LX Zhang, H Fu, XP Dong, YX Cheng	15/06/2012
14-3-3 checkpoint regulatory proteins interact specifically with DNA repair protein human exonuclease 1 (hEXO1) via a semi-conserved motif. DNA repair	SD Andersen, G Keijzers, E Rampakakis, K Engels, P Luhn, M El-Shemerly, FC Nielsen, Y Du, A May, VA Bohr, S Ferrari, M Zannis-Hadjopoulos, H Fu, LJ Rasmussen	01/03/2012
Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proceedings of the National Academy of Sciences of the United States of America	J Jiang, T Ganesh, Y Du, Y Quan, G Serrano, M Qui, I Speigel, A Rojas, N Lelutiu, R Dingledine	21/02/2012
Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor. Proceedings of the National Academy of Sciences of the United States of America	J Zhao, Y Du, JR Horton, AK Upadhyay, B Lou, Y Bai, X Zhang, L Du, M Li, B Wang, L Zhang, JT Barbieri, FR Khuri, X Cheng, H Fu	27/09/2011
A novel high-throughput screening assay for discovery of molecules that increase cellular tetrahydrobiopterin. Journal of biomolecular screening	L Li, Y Du, W Chen, H Fu, DG Harrison	01/09/2011
14-3-3 proteins as potential therapeutic targets. Seminars in cell & developmental biology	J Zhao, CL Meyerkord, Y Du, FR Khuri, H Fu	01/09/2011
A dual-readout F2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions. Assay and drug development technologies	Y Du, Z Nikolovska-Coleska, M Qui, L Li, I Lewis, R Dingledine, JA Stuckey, K Krajewski, PP Roller, S Wang, H Fu	01/08/2011
Discovering small-molecule estrogen receptor α/coactivator binding inhibitors: high-throughput screening, ligand development, and models for enhanced potency. ChemMedChem	A Sun, TW Moore, JR Gunther, MS Kim, E Rhoden, Y Du, H Fu, JP Snyder, JA Katzenellenbogen	04/04/2011
Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proceedings of the National Academy of Sciences of the United States of America	R Cencic, DR Hall, F Robert, Y Du, J Min, L Li, M Qui, I Lewis, S Kurtkaya, R Dingledine, H Fu, D Kozakov, S Vajda, J Pelletier	18/01/2011
Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway. Journal of medicinal chemistry	X Qiu, Y Du, B Lou, Y Zuo, W Shao, Y Huo, J Huang, Y Yu, B Zhou, J Du, H Fu, X Bu	09/12/2010
Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. Biochemical pharmacology	SL Thomas, J Zhao, Z Li, B Lou, Y Du, J Purcell, JP Snyder, FR Khuri, D Liotta, H Fu	01/11/2010
Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. The Journal of pharmacology and experimental therapeutics	KB Hansen, P Mullasseril, S Dawit, NL Kurtkaya, H Yuan, KM Vance, AG Orr, T Kvist, KK Ogden, P Le, KM Vellano, I Lewis, S Kurtkaya, Y Du, M Qui, TJ Murphy, JP Snyder, H Bräuner-Osborne, SF Traynelis	01/06/2010
Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proceedings of the National Academy of Sciences of the United States of America	J Jiang, T Ganesh, Y Du, P Thepchatri, A Rojas, I Lewis, S Kurtkaya, L Li, M Qui, G Serrano, R Shaw, A Sun, R Dingledine	02/02/2010
Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screening. Molecular cancer therapeutics	AB Bialkowska, Y Du, H Fu, VW Yang	01/03/2009
Cancer and virus leads by HTS, chemical design and SEA data mining. Current topics in medicinal chemistry	P Thepchatri, J Min, T Ganesh, Y Du, I Lewis, S Kurtkaya, A Prussia, L Li, B Sneed, RK Plemper, H Fu, DC Liotta, JP Snyder, R Dingledine, A Sun	01/01/2009
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. Journal of receptor and signal transduction research	Y Du, Z Li, L Li, ZG Chen, SY Sun, P Chen, DM Shin, FR Khuri, H Fu	01/01/2009
A homogenous luminescent proximity assay for 14-3-3 interactions with both phosphorylated and nonphosphorylated client peptides. Current chemical genomics	Y Du, FR Khuri, H Fu	06/11/2008
Synthesis and SAR study of N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl)phenyl)-arylsulfonamides: heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in vitro assay. Bioorganic & medicinal chemistry letters	T Ganesh, P Thepchatri, L Li, Y Du, H Fu, JP Snyder, A Sun	15/09/2008
Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Molecular pharmacology	AL Kasinski, Y Du, SL Thomas, J Zhao, SY Sun, FR Khuri, CY Wang, M Shoji, A Sun, JP Snyder, D Liotta, H Fu	01/09/2008
High-throughput screening-based identification of paramyxovirus inhibitors. Journal of biomolecular screening	JJ Yoon, D Chawla, T Paal, M Ndungu, Y Du, S Kurtkaya, A Sun, JP Snyder, RK Plemper	01/08/2008
Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling. Bioorganic & medicinal chemistry	T Ganesh, J Min, P Thepchatri, Y Du, L Li, I Lewis, L Wilson, H Fu, G Chiosis, R Dingledine, D Liotta, JP Snyder, A Sun	15/07/2008
Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proceedings of the National Academy of Sciences of the United States of America	Z Li, J Zhao, Y Du, HR Park, SY Sun, L Bernal-Mizrachi, A Aitken, FR Khuri, H Fu	08/01/2008
Inhibition of Protein-Protein Interactions: Non-Cellular Assay Formats Assay Guidance Manual	MR Arkin, MA Glicksman, H Fu, JJ Havel, Y Du	01/01/2004